Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Connective Tissue Cell Types

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Biological treatments for rheumatology : specific situations and risks].

Revue medicale suisse·2026

Same author

[Rheumatology : what's new in 2025].

Revue medicale suisse·2026

Same author

[Biological treatments for rheumatology : demystifying the risks].

Revue medicale suisse·2025

Same author

BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis.

Rheumatology advances in practice·2025

Same author

Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases.

RMD open·2023

Same author

The Global Spine Care Initiative: model of care and implementation.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2018

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 30, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

[Rheumatology: what's new in 2024].

Marie Dudler¹, Jean Dudler¹

¹Service de rhumatologie, HFR Fribourg, 1708 Fribourg.

Revue Medicale Suisse

|January 30, 2025

Summary

This summary is machine-generated.

CD19-CAR T cell therapy shows remarkable results in severe rheumatology, offering potential drug-free remission. However, high costs and limited long-term data remain challenges, while new targeted treatments emerge for specific inflammatory conditions.

More Related Videos

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

Related Experiment Videos

Last Updated: May 30, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

Area of Science:

Immunotherapy
Rheumatology

Context:

CD19-CAR T cells are increasingly utilized in rheumatology for severe, refractory diseases.
B lymphocyte targeting shows significant therapeutic potential.

Purpose:

To review the current status and future prospects of CD19-CAR T cell therapy in rheumatology.
To discuss emerging targeted therapies for giant cell arteritis and polymyalgia rheumatica.

Summary:

CD19-CAR T cell therapy demonstrates impressive efficacy and tolerability in severe autoimmune conditions, hinting at drug-free remission possibilities.
Despite its success, high costs and the need for long-term outcome data limit its accessibility.
Targeted treatments like JAK inhibitors, anti-IL17, and sarilumab are nearing availability for giant cell arteritis and polymyalgia rheumatica, offering corticosteroid-sparing benefits.

Impact:

Advances in CAR T-cell therapy offer new hope for patients with difficult-to-treat rheumatic diseases.
Emerging targeted therapies promise improved management and reduced reliance on corticosteroids for specific inflammatory conditions.
The high cost of CAR T-cell therapy necessitates further research into accessibility and cost-effectiveness.